Kit for detecting the A1298C polymorphism of the MTHFR gene by Real Time PCR using TaqMan® probes technology

Information about the product

Methylenetetrahydrofolate reductase (MTHFR) is a key enzyme in folate metabolism. Although MTHFR protein does not participate in the clotting cascade as other proteins such as FII and FV (and therefore belonging to the well-known group of coagulation factors), the involvement of MTHFR in the folate metabolic pathway may affect thrombophilia development, as well as increased cancer risk or Alzheimer’s disease appearance.

MTHFR gen can present different polymorphisms. The most common and studied variant is the MTHFR C677T polymorphism but, also, the MTHFR A1298C mutation has been studied. The frequency of both MTHFR polymorphisms differs among the different ethnicities.

Intended Use

Genvinset® MTHFR A1298C is a semi-automated kit for the in vitro qualitative detection of the A1298C polymorphism (NCBI dbSNP rs1801131; NM_001330358.2:c.1409A>C) in the Methylene tetrahydrofolate reductase (MTHFR) gene (OMIM: 607093) associated with thrombophilia risk in genomic DNA extracted from whole blood using Real Time PCR technology with specific TaqMan® probes.

Patients who can benefit from this determination are those referred by a specialist. The results of this test should not be the only ones on which the therapeutic decision is based and should be used as an aid in the diagnosis together with results of other markers of the disease.

The intended user of the kit is technical personnel trained to carry out the protocol and the interpretation of results described in the instructions for use.

Genvinset® MTHFR A1298C is a kit for the in vitro qualitative detection of the A1298C polymorphism (NCBI dbSNP rs1801131; NM_001330358.2:c.1409A>C) in the Methylene tetrahydrofolate reductase (MTHFR) gene (OMIM: 607093) associated with thrombophilia risk in genomic DNA extracted from whole blood using Real Time PCR technology with specific TaqMan® probes.

Patients who can benefit from this determination are those referred by a specialist. The results of this test should not be the only ones on which the therapeutic decision is based and should be used as an aid in the diagnosis together with results of other markers of the disease.

The intended user of the kit is technical personnel trained to carry out the protocol and the interpretation of results described in this document.

Workflow

workflow genvinset 2

Results

Genvinset MTHFR A1298C Heterozygous sample
Genvinset MTHFR A1298C Homozygous mutated sample
Genvinset® MTHFR A1298C 6
Genvinset MTHFR A1298C Homozygous wildtype sample
Genvinset® MTHFR A1298C 7
leyenda 12

Limitations

  • Mutations or polymorphisms at annealing primer/probe sites are possible and may result in the lack of allele definition. Other technologies could be necessary to resolve the typing.
  • Data and result interpretation should be revised by qualified personnel.
  • This product is an auxiliary tool for the diagnosis of patients with suspected thrombophilia. Use these results in conjunction with clinical data and results of other tests performed on the patient.

Area:

Hematology, Molecular Genetics, Thrombophilias, Thrombophilias

Documents:

Consult our experts

Google reCaptcha: Invalid site key.

Related products

SOPHiA DDM GEN2

Analytical platform for clinical genomics that enables the detection, annotation, and interpretation of genomic variants using artificial intelligence to support patient diagnosis and treatment. Detailed Description SOPHiA DDM™ Platform is an advanced solution for precision medicine workflows, with a renewed interface, web access, and new functionalities to accelerate genomic data analysis. It offers end‑to‑end workflows…
SOPHIA Genetics

PGT-SR (Preimplantation Genetic Testing for Chromosomal Structural Rearrangements)

PGT‑SR (Preimplantation Genetic Testing for Structural Chromosomal Rearrangements) is a solution aimed at the analysis of structural chromosomal rearrangements in embryos. According to the product literature, it is based on single‑cell whole‑genome amplification and NGS sequencing to detect embryos from patients with chromosomal abnormalities and select euploid embryos for transfer, with the aim of reducing…
Yikon Genomics
Next Generation Sequencing (NGS)

MaReCs (Mapping allele with resolved carrier state test)

MaReCs® (Allelic Mapping with Resolved Carrier Status) is a PGT‑SR technology that first identifies aneuploid or euploid embryos and then analyses translocation breakpoints and SNP linkage to differentiate carrier from non‑carrier euploid embryos. Detailed Description Principle of operation MaReCs® combines ChromSwift® technology with NGS sequencing to perform a CNV analysis and subsequently an SNP linkage…
Yikon Genomics
Next Generation Sequencing (NGS)

KaryoSeq (Integrated solution for PGT-M, PGT-SR and PGT-A)

KaryoSeq™ is a next‑generation sequencing (NGS)‑based solution for preimplantation genetic testing that enables PGT‑M, PGT‑SR and PGT‑A within a single workflow. It is designed for the analysis of DNA extracted from 3 to 10 trophectoderm cells of human embryos at the blastocyst stage. Detailed Description Principle of operation KaryoSeq™ is based on the MARSALA principle…
Yikon Genomics
Next Generation Sequencing (NGS)